AstraZeneca remains a long-term buy, driven by a diversified portfolio, robust R&D, and strong FCF, despite a current valuation that is slightly stretched. AZN's 2025 results showed 8% revenue and 11% EPS growth, with oncology (44% of revenue) and rare diseases as key growth engines. Patent expirations for Farxiga and price pressures in China pose near-term headwinds, but pipeline innovation and emerging market growth underpin future prospects.